San Francisco, CA USA
October 10-11, 2018


Read the Review of Last Year's Summit

Featured Speakers

Nathaniel Katz, MD., Chief Executive Officer, Analgesic Solutions
Mike Royal, MD, Chief Medical Officer, Concentric Analgesics
Neil Singla, MD, Chief Scientific Officer, Lotus Clinical Research

Webinar Series

A New Gentle Model of Neuropathic Pain 
Mary Hannaman, MD, President and Founder, Neurodigm

By using the new biomimetic model of neuropathic pain, your preclinical program can replace the Chung model, discover how opiates act over time and explore targeted biologics.

CLICK HERE to view the replay.

2011i.gif 2011ii.JPG 2011iii.JPG 2014i.JPG 2014ii.JPG 2014iii.JPG 2015i.JPG 2015ii.JPG

Join our Social Media Groups

                 Pain Drug Development Group                               

About the Conference

ARROWHEAD’S ANNUAL PAIN & MIGRAINE THERAPEUTICS SUMMIT is the US’s premier pain conference covering the field of pain research and therapeutics. Leaders from the pharmaceutical, biotech, device and medical communities attend this conference to learn about the latest advances in the treatment of various types of pain and to network with colleagues from industry, the non-profit sector, academia, the medical community, government and investors.
This conference provides attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products. We will highlight the most important developments in recent years in the field, including:

♦ Clinical Trial Design and Endpoints for Pain
♦ Emerging Pain Research from Industry, Academia and Government
♦ CGRP Antagonist Research and Clinical Trial Data
♦ The Latest Diagnostic Imaging Research
♦ NGF antagonist Research and Clinical Trial Data
♦ Emerging Trends and New Animal Model Research
♦ Nociceptive Pain, Neuropathic Pain, Inflammatory Pain, Migraine Pain, Post-Operative Pain, Cancer Pain and Other Types

♦ New Research in Biologic Therapy Development
♦ Non-Opiate Pain Drug Development Trends and Clinical Development Programs
♦ Sodium and Calcium Channel Blocker Research and Clinical Trials
♦ The Genetic Components of Pain
♦ Abuse-resistant Opioid Drug Development
♦ Analysis of FDA’s REMS program
...and a plethora of other topics.

2017 Sponsors

Download Brochure

Speaking Opportunities

Sponsor/Exhibit Opportunities

Join Conference Mailing List

Testimonials from Past Summits

I enjoyed the experience and thought the program was a lovely balance of topics across advances in the development space and in the laboratory. The ease to meet and speak to people was also excellent.
Nick Andrews, Instructor and Manager, <strong>Boston Children's Hospital/Harvard Medical School</strong>
Nick Andrews, Instructor and Manager, Boston Children's Hospital/Harvard Medical School

The Arrowhead Summit is a comprehensive mix of the latest in pre-clinical, mechanistic work in pain drug development along with a nice overview of current clinical trial advancements in this therapeutic area.
Paul Blahunka, Global Development Project Leader, <strong>Astellas</strong>
Paul Blahunka, Global Development Project Leader, Astellas

A great meeting to get to know those on the forefront of pain development.
Mike Royal, EVP, Clinical & Regulatory Affairs, <strong>Sorrento Therapeutics</strong>
Mike Royal, EVP, Clinical & Regulatory Affairs, Sorrento Therapeutics

I very much enjoyed the scientific content and the size of the meeting.
Carol Meschter, <strong>Comparative Biosciences, Inc.</strong>
Carol Meschter, Comparative Biosciences, Inc.

This is always a delightful and informative session.
Steve Shulman, Assistant Clinical Professor of Anesthesiology and Pain Medicine, <strong>Rutgers-NJMS/Newark</strong>
Steve Shulman, Assistant Clinical Professor of Anesthesiology and Pain Medicine, Rutgers-NJMS/Newark

It is a nice snapshot of scientific activity and a look at what may be on the horizon in the pain space.
Nicole McGrew, Project Director, <strong>INC Research</strong>
Nicole McGrew, Project Director, INC Research

The conference was a very well balanced session with high quality, innovative attendees, informative sessions and great organization. I'm excited for next year's conference.
Christopher Frankiewicz, Research Scientist, <strong>Chromocell Corporation</strong>
Christopher Frankiewicz, Research Scientist, Chromocell Corporation

Who Attends

Abbott Laboratories | Acura Pharmaceuticals | Adolor Corporation | Adynxx Inc. | Aestus Therapeutics | Afferent Pharmaceuticals | AIT Laboratories | Alder Biopharmaceuticals | Algos Preclinical Services | Alta Life Sciences LLC | Ameritox | Amgen | Anabios Corporation | Analgesic Solutions | Anvyl LLC | Archimedes Pharma | Arcion Therapeutics | Array Biopharma | Astellas Pharma Europe | AstraZeneca | Atlantic Pharmaceuticals Inc | Avigen | Benitec Biopharma | BioAssets Development Corporation | Biogen Idec | BioLineRx | Bionomics | bvBiovail | BioVasc Inc. | Cadence Pharmaceuticals | Camargo Pharma Services | Cambridge Consultants Ltd. | Cara Therapeutics | Cardiome Pharma Corp. | Carnegie Mellon University | Celgene Corp. | Cephalon, Inc. | CG Pharmaceuticals | ChanTest | Chromocell Corporation | Clinical Trial Centers | Clinsys Clinical Research | CNS Drug Consulting | CNSBio Inc. | COLLEGIUM Pharma | Covidien | CRI Lifetree | CRI Worldwide | CrystalGenomics, Inc. | Cubist Pharmaceuticals | DARA BioSciences, Inc | Decision Line Clinical | Defined Health | Dendreon Corporation | Depomed | Domain Associates | Dr. Kade Pharma GmbH | Dr. Reddy's Laboratories | DURECT Corporation | Elanco Animal Health | Eli Lilly & Co | Ethypharm USA | Eurand | Eurofins Prod Safety Labs | FDA | Forest Research Institute | Franklin Pharmacy | Genentech | Genzyme | GIST | GlaxoSmithKline | Glenmark Therapeutics Inc. | Grünenthal GmbH | GVK Biosciences | GW Pharma | Hospira, Inc. | Hydra Biosciences | i3 Research | Icagen | ICON Development | I-Flow, LLC | Indiana University | INFARMED, .I.P. | Integrated Circle of Care Inc. | Ironwood Pharmaceuticals | Isis Pharmaceuticals | J. Bolen Group, LLC | Janssen Pharmaceuticals | Janssen Research | Javelin Pharmaceuticals | Jennersville Hospital | Johnson & Johnson Pharmaceutical | KAI Research Inc. | KCI | King Pharmaceuticals | Labopharm Inc. | Lotus Clinical Research | Lpath | Mass. General Hospital | McGill University | McLean Hospital | MD Biosciences | MedImmune | Medtox Laboratories | Medtronic | Merck & Co., Inc. | Millipore | Mitsubishi Tanabe | MRC Technology | Natixis Bleichroeder | Nektar Therapeutics | NeurAxon | NeuroDiscovery Group | Neuromed | Newron Pharma | NINR, NIH | NMS Labs | North Star Consulting | NovaBay Pharma | Noveida | Nuvo Research | Nycomed | NYU School of Medicine | Omneuron, Inc. | Orexo AB | Origin BioMed Inc. | Ormskirk Hospital | Pacira Pharmaceuticals | Pain Ceptor Pharma | Pain Insights, Inc. | Pain Research Forum | PainReform | Pappas Ventures | PAREXEL International | Pfizer VMRD | PharmacoFore | PharmaNet-i3 | Pharmidex | Phosphagenics | PLX Pharma | Precise Clinical Research | Premier Research | Prescription Drug Research Center | Product Safety Labs | PsychoGenics Inc. | Purdue Pharma | QRx Pharma | Radical Group | Regeneron | Regeneron Pharmaceuticals | ResearchPoint | Ricerca Biosciences | RoxRo Pharma | sanofi Aventis | Schwarz BioSciences | SCOLR Pharma | Scripps Research Institute | Sepracor | Shaare Zedec Medical Center | Shire Pharmaceuticals | Solimar Therapeutics, Inc. | St. Louis University | Stanford Pain Medicine Center | Stanford University | Stanford University School of Medicine | Studylog Systems | Sungsil University | Sunovion Pharmaceticals| Susquehanna Financial | Synergenics, LLC | Synergy Clinical Research | Syntaxin Ltd | Takeda Pharmaceutical Company | Temple Univ. Beasley School of Law | Temple University School of Pharmacy | Teva Pharmaceuticals | The May Day Fund |The Pain Treatment Center of the Bluegrass | The Scripps Research Institute | Theorem Clinical Research | TheraQuest Biosciences | Theravance | Trevena Inc. | Trillium Medical Ventures | Trinity Partners | U. Iowa Carver College of Med., Dept. of Pharmacology & Anesthesia | UC Davis | UCSD | UCSF | UMDNJ | University of Adelaide | University of Arizona | University of California San Francisco | University of California, Irvine | University of Kentucky | University of Pittsburgh | University of Rochester Medical Center | Vertex Pharmaceuticals | Victory Pharma | Vince and Associates Clinical Research | Vivozon, Inc | VM Pharma | Washington University | Washington University in St. Louis | Wright State University School of Medicine | Wyeth | Wyeth Research | Xalud Therapeutics | Xanodyne Pharmaceuticals | Xenome | Xenon Pharmaceuticals Inc. | XenoPort | Zalicus | Zogenix

About Us

Arrowhead Publishers' conferences offer more than simply presentations; we offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward. 

Contact Us

For general information about the conference, please contact us at:
 This email address is being protected from spambots. You need JavaScript enabled to view it.
  PO Box 96, Chanhassen, MN 55317 USA


Join Our Mailing List
Please fill out the following form in order to receive occasional updates regarding this conference, including updates regarding the agenda, speaker additions and conference promotions and DISCOUNTS.
We never share your personal data with anyone else, EVER!
Michael G. Palfreyman, Ph.D., DSc.

Chief Scientific Officer, Amorsa Therapeutics

Michael Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years experience in drug discovery, pre-clinical and early clinical development. He has directed research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman’s own research includes discovery and development of a number of psychotherapeutic compounds including antipsychotics, antidepressants, anti-epileptics, analgesics, anti-Parkinson’s, anti-emetics, cognition enhancers and Alzheimer’s treatments. Many of these compounds have entered clinical development and a number have reached the market place. 

He is a Fellow of the American College of NeuroPsychopharmacology and he is a qualified Pharmacist and Founding Member Royal Pharmaceutical Society of Great Britain. He is the co-inventor of 53 issued US and European patents, 4 pending patents and co-author of over 100 peer reviewed scientific articles, has edited books on glutamate antagonists and enzyme inhibitors and authored several book chapters on a number of different therapeutics. He is currently Chief Scientific Officer at Amorsa Therapeutics.